Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study

被引：0
|
作者：
Xueli Nan
Chao Xie
Qingqing Zhu
Jianjun Zhang
Shuai Fu
Xiao Han
Qiujing Zhang
Baohui Han
Jie Liu
机构：
[1] Shandong First Medical University and Shandong Academy of Medical Sciences,Department of Oncology
[2] Wu Di People Hospital,Department of Oncology
[3] Shandong Cancer Hospital and Institute,School of Medicine and Life Sciences
[4] University of Ji’nan-Shandong Academy of Medical Sciences,Department of Pulmonary Medicine
[5] Shanghai Chest Hospital,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Non-small-cell lung cancer; Anlotinib; Adverse event; Clinical marker;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1492 / 1498
页数：6
相关论文
共 50 条
  • [41] Erlotinib in patients with advanced non-small-cell lung cancer: a meta-analysis
    Gao, Hui
    Ding, Xin
    Wei, Dong
    Cheng, Peng
    Su, Xiaomei
    Liu, Huanyi
    Aziz, Fahad
    Wang, Daoyuan
    Zhang, Tao
    TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (02) : 129 - 144
  • [42] Stage IV Non-Small-Cell Lung Cancer in Older Patients: Survival analysis
    Yu, Chin-Hsiu
    Wu, Yu-Lung
    Chen, Ru-Yih
    Cheng, Ya-Ai
    Lin, Min-Hsi
    PSYCHO-ONCOLOGY, 2018, 27 : 112 - 113
  • [43] Analysis of the characteristics and prognosis of advanced non-small-cell lung cancer in older patients
    Gao, Ying
    Gao, Fei
    Ma, Jin-lu
    Zhang, Xiao-zhi
    Li, Yi
    Song, Li-ping
    Zhao, Dong-li
    PATIENT PREFERENCE AND ADHERENCE, 2015, 9 : 1189 - 1194
  • [44] An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer
    Bosken, CH
    Wei, QY
    Amos, CI
    Spitz, MR
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (14): : 1091 - 1099
  • [45] Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Johnson, Faye M.
    Bekele, B. Nebiyou
    Feng, Lei
    Wistuba, Ignacio
    Tang, Xi Ming
    Tran, Hai T.
    Erasmus, Jeremy J.
    Hwang, Li-Ling
    Takebe, Naoko
    Blumenschein, George R.
    Lippman, Scott M.
    Stewart, David J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) : 4609 - 4615
  • [46] Osteonecrosis of the Jaw in a Patient With Advanced Non-Small-Cell Lung Cancer Receiving Bevacizumab
    Katsenos, Stamatis
    Christophylakis, Charalampos
    Psathakis, Konstantinos
    ARCHIVOS DE BRONCONEUMOLOGIA, 2012, 48 (06): : 218 - 219
  • [47] Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 clinical trial (vol 4, pg 1569, 2018)
    Han, B.
    Li, K.
    Wang, Q.
    JAMA ONCOLOGY, 2018, 4 (11) : 1625 - 1625
  • [48] Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
    Zhang, H.
    Guttikonda, S.
    Roberts, L.
    Uziel, T.
    Semizarov, D.
    Elmore, S. W.
    Leverson, J. D.
    Lam, L. T.
    ONCOGENE, 2011, 30 (16) : 1963 - 1968
  • [49] Circadian function in patients with advanced non-small-cell lung cancer
    Levin, RD
    Daehler, MA
    Grutsch, JF
    Quiton, J
    Lis, CG
    Peterson, C
    Gupta, D
    Watson, K
    Layer, D
    Huff-Adams, S
    Desai, B
    Sharma, P
    Wallam, M
    Delioukina, M
    Ball, P
    Bryant, M
    Ashford, M
    Copeland, D
    Ohmori, M
    Wood, PA
    Hrushesky, WJM
    BRITISH JOURNAL OF CANCER, 2005, 93 (11) : 1202 - 1208
  • [50] Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients
    Nasser, Fabio
    Souza Cruz, Marcelo Rocha
    Riera, Rachel
    JAMA ONCOLOGY, 2016, 2 (12) : 1645 - 1646
12345